Bio Spectrum - September 2017
English | 54 pages | True PDF | 11.4 MB
English | 54 pages | True PDF | 11.4 MB
Shortage In Europe of Oncology Drugs… An opportunity for Indian Pharma?
Indian drug companies are facing strong headwinds due to prompt regulatory action of United States Food and Drug Administration (USFDA), likely imposition of Border Adjustment Tax (BAT) and delay in new drug approvals. Probably, it is the best time for Indian pharma companies to explore opportunities and business in the European market.